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Abstract  
Transcatheter aortic valve implantation (TAVI) was initially 
reserved for inoperable or high surgical risk patients with severe 
symptomatic aortic valve stenosis, but after the recent 
publication of randomized studies comparing TAVI to surgical 
aortic valve replacement (AVR) among intermediate risk 
(PARTNER 2 and SURTAVI) and low risk patients (PARTNER 
3 and Evolut Low Risk), the momentum for further expansion of 
TAVI at the expense of AVR seems irreversible. The main 
obstacle before the wider application of TAVI for intermediate 
and lower risk patients is the uncertainty regarding bioprosthetic 
valve durability and the potential for structural deterioration and 
dysfunction over time. A concise overview regarding 
bioprosthetic valve durability issues, the relevant current 
scientific data and their importance for TAVI patient selection 
and management is herein presented. Rhythmos 2020;15(1):6-
10.  
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Abbreviations: AVR = aortic valve replacement; BVF = 
bioprosthetic valve failure; HALT = hypoattenuated leaflet 
thickening; MDCT = multidetector computed tomography; PET-
CT = positron emission tomography-computed tomography; 
PPM = patient-prosthesis mismatch; RELM = reduced leaflet 
motion; SVD = structural valve deterioration; TAVI = 
transcatheter aortic valve implantation 
 
Introduction 
 
During the last 20 years, the treatment of severe aortic 
valve stenosis (AS) has evolved dramatically. Surgical 
aortic valve replacement (AVR) techniques have been 
optimized, as with the more frequent use of new generation 
bioprosthetic sutureless valves which decreases 
significantly the aortic cross-clamp time. But the most 
significant evolution has undisputedly been the expansion 
of transcatheter aortic valve implantation (TAVI) that has 
revolutionized the treatment of severe AS, which is the 
most common valvular heart disease. Irrespective of the 
interventional technique selected (TAVI or AVR), any 
given patient older than 65 years will most probably 
receive a bioprosthetic aortic valve.1 Depending on his life 
expectancy, the treating physician should anticipate the 
immutable degradation of prosthetic biological tissues and 
be vigilant for the advent of bioprosthetic valve structural 
deterioration and possible dysfunction. The medium and 
long-term durability of the new bioprosthetic aortic valves, 
especially those implanted with TAVI, constitutes a 
burning question and possibly the final frontier before 
TAVI domination over AVR for the treatment of severe 
AS. 
 
Significant recent studies heralding further expansion 
of TAVI  
The most recent valvular heart disease management 
guidelines recommend TAVI for patients inoperable or at 
very high surgical risk, but also for patients at intermediate 
surgical risk based on data of two recently published large 
randomized trials, PARTNER 2 and SURTAVI.1 
The PARTNER 2 study randomly assigned 2032 
intermediate-risk patients with severe AS to undergo either 
TAVI (1001 patients, mean age 81.5 years) or AVR (1021 
patients, mean age 81.7 years). 2 The primary end point 
was death from any cause or disabling stroke at 2 years. 
The valve used for TAVI was the balloon-expandable 
Sapien XT (Edwards Lifesciences). Before randomization, 
patients were entered into one of two cohorts on the basis 
of clinical and imaging findings; 76.3% of the patients 
were included in the transfemoral-access cohort and 23.7% 
in the transthoracic-access cohort. The rate of death from 
any cause or disabling stroke was similar in the TAVI 
group and the AVR group. At 2 years, the event rates were 
19.3% in the TAVI group and 21.1% in the AVR group 
(hazard ratio-HR in the TAVI group, 0.89, p=0.25). In the 
transfemoral-access cohort, TAVI resulted in a lower rate 
of death or disabling stroke than AVR (HR 0.79, p=0.05), 
whereas in the transthoracic-access cohort outcomes were 
similar in the two groups. TAVI compared to AVR 
resulted in larger aortic-valve areas and also in lower rates 
of acute kidney injury, severe bleeding, and new-onset 
atrial fibrillation, while AVR compared to TAVI resulted 
in fewer major vascular complications and less 
paravalvular aortic regurgitation.2 
The SURTAVI study evaluated the clinical outcomes 
of 1660 intermediate-risk patients with symptomatic 
severe AS in a randomized trial comparing TAVI 
(performed with the use of a self-expanding prosthesis: 
CoreValve 86%, Evolut R 14%, Medtronic) with AVR. 
The mean (±SD) age of the patients was 79.8±6.2 years, 
and all were at intermediate risk for surgery (Society of 
Thoracic Surgeons – STS Predicted Risk of Mortality, 
4.5±1.6%). The primary end point was a composite of 
death from any cause or disabling stroke at 24 months. At 
24 months, the estimated incidence of the primary end 
point was 12.6% in the TAVI group and 14% in the AVR 
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group (probability of noninferiority, p >0.999). TAVI had 
higher rates of residual aortic regurgitation and need for 
pacemaker implantation, but resulted in lower mean 
gradients and larger aortic-valve areas than AVR, which 
was associated with higher rates of acute kidney injury, 
atrial fibrillation, and transfusion requirements. Structural 
valve deterioration at 24 months did not occur in either 
group. Consequently TAVI constitutes a non-inferior 
alternative to AVR, yet with differences regarding the 
probability of associated events.3 
There have also been recently published data regarding 
the comparison of TAVI to AVR among low risk patients 
with severe aortic valve stenosis coming from the 
PARTNER 3 and Evolut Low Risk studies. 
The PARTNER 3 study randomly assigned 1000 
patients with severe AS and low surgical risk (mean age 73 
years, mean STS risk score 1.9%) to undergo either TAVI 
with transfemoral implantation of a balloon-expandable 
valve (Sapien 3, Edwards Lifesciences) or surgery. The 
primary end point was a composite of death, stroke or 
rehospitalization at 1 year and it was significantly lower in 
the TAVI group than in the surgery group (8.5% vs. 
15.1%; p<0.001 for noninferiority; HR, 0.54; p = 0.001 for 
superiority). At 30 days, TAVI compared to AVR resulted 
in lower rates of stroke (p=0.02), death or stroke (p=0.01) 
and new-onset atrial fibrillation (p<0.001), while it also 
resulted in a shorter index hospitalization (p<0.001) and in 
a lower risk of a poor treatment outcome (p<0.001). There 
were no significant between-group differences in major 
vascular complications, new pacemaker insertions, or 
moderate or severe paravalvular regurgitation.4 
In the Evolut Low Risk study, TAVI with a self-
expanding supra-annular bioprosthesis (Evolut R, 
Medtronic) was compared with AVR among 1468 
randomized patients who had severe AS and were at low 
surgical risk. The primary end point, a composite of death 
or disabling stroke at 24 months, had an incidence of 5.3% 
in the TAVI group and of 6.7% in the AVR group 
(probability of noninferiority p >0.999). At 30 days, 
patients who had undergone TAVI, as compared with 
AVR, had a lower incidence of disabling stroke (0.5% vs. 
1.7%), bleeding complications (2.4% vs. 7.5%), acute 
kidney injury (0.9% vs. 2.8%), and atrial fibrillation (7.7% 
vs. 35.4%) and a higher incidence of moderate or severe 
aortic regurgitation (3.5% vs. 0.5%) and pacemaker 
implantation (17.4% vs. 6.1%). At 12 months, patients in 
the TAVI group had lower aortic-valve gradients than 
those in the surgery group (8.6 mm Hg vs. 11.2 mm Hg) 
and larger effective orifice areas (2.3 cm2 vs. 2.0 cm2).5 
Thus, both PARTNER 3 and Evolut Low risk were 
positive studies that reached their primary objective of 
non-inferiority of TAVI over AVR; furthermore, 
PARTNER 3 has demonstrated superiority of TAVI over 
AVR. Therefore, TAVI has the potential to become the 
treatment of reference for symptomatic severe AS instead 
of AVR, with the final decision to be taken in each case by 
the Heart Team. Severe AS is a disease of the elderly with 
the average patient being more than 80-year-old and the 
current trend is to choose TAVI as treatment for elderly 
active patients, with active social life demanding to keep 
up with their activities. However, for intermediate or low 
risk patients the follow-up data are relatively short and it 
cannot be certain that TAVI would be non-inferior to AVR 
in younger populations, where the probability of structural 
valve deterioration (SVD) and bioprosthetic valve failure 
(BVF) over time is a major issue. SVD is more common in 
younger patients, while studies of both the initial and 
current TAVI devices included mainly elderly patients. 
Logically, it will take several years and possibly a decade, 
before younger, lower risk patients undergoing TAVI will 
enable reliable long-term follow-up data collection 
concerning the long-term durability of TAVI devices.6 
 
Bioprosthetic valve structural deterioration: 
definitions and diagnosis 
The echocardiographic evaluation of valve 
morphology (morphologic deterioration) and function 
(hemodynamic deterioration) is the key element to 
evaluate if SVD exists.7,8 SVD usually presents as leaflet 
calcification resulting in stenosis, but also as leaflet flail or 
tear resulting in regurgitation. Early SVD is associated 
with several well known risk factors such as young patient 
age, renal failure, abnormal calcium metabolism, and 
prosthesis-patient mismatch of the implanted valve.9 The 
exact echocardiographic criteria of SVD and the relevant 
hemodynamic quantitative parameters were not 
determined until recently, when the publication of 2 papers 
proposed standardized definitions. Two different expert 
groups provided such definitions: one European (including 
EAPCI, ESC and EACTS) and one international (group 
VIVID: Valve-in-Valve International Data ).10,11  
These two papers provide definitions that have many 
similarities and few differences, but their in-depth analysis 
is beyond the scope of this article. They both recommend 
to perform a reference echocardiography post-
implantation and a systematic echocardiographic 
assessment annually. This follow-up plan allows the early 
detection of structural deterioration signs as well as any 
non-structural dysfunction. Any signs of morphologic 
deterioration of the bioprosthetic leaflets (structural or 
motion abnormality) even if they are not associated with 
clinically significant functional degradation of the 
bioprosthetic valve should lead to a diagnosis of structural 
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deterioration. Any hemodynamic deterioration is defined 
as functional degradation of the bioprosthetic valve 
compared to the reference echocardiography, such in case 
of increase of the mean gradient and/or appearance (or 
aggravation) of intra-bioprosthetic regurgitation. The 
hemodynamic deterioration is classified in grades of 
increasing severity compared to the reference 
echocardiography post-implantation: moderate or severe 
dysfunction according to the European societies and stages 
2 and 3 for the international VIVID definition.10,11 The 
designation of a stage that combines echocardiographic 
deterioration and clinical repercussions as bioprosthetic 
valve failure (BVF) facilitates the study of the clinical 
impact of any structural deterioration.10  
The limits of transthoracic echocardiography to detect 
and analyze tissue lesions of bioprosthetic valve leaflets 
create the necessity of using other imaging modalities. The 
transesophageal echocardiography allows in certain cases 
to objectively assess the presence of leaflet tissue lesions 
and rule out other alternative diagnoses. Multidetector 
computed tomography (MDCT) without contrast agent 
allows the detection of bioprosthetic leaflet calcifications 
which is an independent predictor of future hemodynamic 
deterioration but also of clinical events, such as death and 
re-intervention.12,13 Furthermore, MDCT with contrast 
agent allows the detection of subclinical bioprosthetic 
leaflet thrombosis in the forms of leaflet thickening 
(HALT: hypoattenuated leaflet thickening) and reduced 
leaflet mobility (RELM: reduced leaflet motion).14 Such 
lesions are more frequently observed in cases of 
bioprosthetic valves implanted with TAVI instead of AVR, 
they are mostly without symptoms, do not cause an 
increase of the mean gradient and are reversible after some 
weeks of therapeutic oral anticoagulation.15 However, 
since there is a continuum linking leaflet thrombosis and 
structural deterioration the persistence of this type of 
lesions despite curative anticoagulation for more than 3 
months should be considered as SVD.16 Finally nuclear 
imaging with positron emission tomography - computed 
tomography (PET-CT) using 18F-fluoride as tissue activity 
marker can predict future development of SVD, but an 
increased uptake can also signify the presence of pannus 
or thrombus.17 According to the recently published 
standardized definitions cardiac imaging thus permits to 
classify SVD in 4 stages (Table 1).10,11  
In conclusion, the annual follow-up with 
echocardiography is the basic and only examination to 
analyze valvular hemodynamic conditions, while MDCT 
and PET-CT can have in occasional cases a 
complementary role in order to add detail to the 
morphologic evaluation and do the differential diagnosis 
of BVF. Clinical criteria should obviously be considered 
to assess the impact of BVF (such as the presence of 
dyspnea, rehospitalization for heart failure, reintervention 
for valve dysfunction and death). 
 
Table 1. Classification of structural valve deterioration  
 
Stage 0 Absence of morphologic abnormality and stability of 
hemodynamic parameters 
Stage 1 Morphologic abnormalities without significant 
hemodynamic deterioration 
Stage 2 Morphologic abnormalities with moderate 
hemodynamic deterioration (stenosis and/or 
regurgitation) 
Stage 3 Morphologic abnormalities with severe hemodynamic 
deterioration (stenosis and/or regurgitation) 
 
Bioprosthetic valve structural deterioration: 
pathophysiology and mechanisms 
Data related to the pathophysiology of SVD are mainly 
derived from studies concerning AVR. The mechanical 
stress on the bioprosthetic valve leaflets is an important 
factor that determines the speed of SVD. Some 
bioprosthetic valve designs related to suboptimal 
hemodynamic results post-intervention show a tendency 
for faster degeneration.13 Patient-prosthesis mismatch 
(PPM) is an important factor promoting early leaflet 
calcification, hemodynamic degeneration and the need for 
secondary reintervention due to severe structural 
dysfunction.12,13,18,19 As the severity of PPM increases the 
risk of hemodynamic deterioration becomes more and 
more important.13 Leaflet calcification is the main lesion 
observed in SVD and is the result of an active 
mineralization phenomenon as shown in histopathologic 
studies.20 The absence of anti-calcification treatment of the 
valve and the presence of dysregulation of calcium and 
phosphorus metabolism participate in this process.12 Renal 
insufficiency and an abnormal renal clearance similarly 
promote early SVD.13 Metabolic abnormalities such as 
diabetes mellitus, dyslipidemia and metabolic syndrome 
are strongly correlated to a risk of early SVD.  
Histopathologic studies of explanted valves have 
confirmed the presence of leucocytes and macrophages 
and a lipid-mediated inflammation in degenerated leaflet 
lesions suggesting an active immune mechanism 
resembling that of atherosclerosis.21 
Common mechanisms seem to pertain to bioprosthetic 
valves implanted percutaneously but several particularities 
related to their design and implantation technique may be 
specifically implicated in the SVD process post-TAVI. 
The percutaneous implantation technique depending on 
the valve type includes crimping, charging of the valve in 
the implantation system, implantation of the valve by 
balloon dilatation and possible optimization with post-
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dilatation. All these steps can lead to alteration of the 
prosthetic leaflets mechanical properties and cause micro-
lesions secondary to valve manipulation that predispose to 
subclinical leaflet thrombosis.22 In certain native aortic 
valve anatomies with severe calcification the bioprosthetic 
valve can be deployed in a non-circular and irregular 
fashion leading to areas of turbulent flow or more 
important mechanical stress upon the leaflets and other 
areas where to the contrary a certain degree of stasis can 
predispose to thrombosis.23,24 Significant oversizing of the 
bioprosthetic valve compared to the native annulus 
dimensions can lead to incomplete expansion with a 
disproportion between leaflets and orifice having as 
consequences increased mechanical stress and turbulent 
transvalvular flow.24 All these implantation issues specific 
to TAVI can explain the increased incidence of subclinical 
thromboses compared to AVR.15 The link found by 
histopathologic studies between thrombosis and structural 
deterioration suggests a theoretical increased risk for SVR 
after TAVI.16,17 However this theoretical increased risk is 
not yet proven in studies. 
 
Bioprosthetic valve durability 
The durability of surgical bioprosthetic valves depends 
on the advent of structural deterioration, its severity and its 
clinical impact. The new generations of surgical bio-
prosthetic valves demonstrate excellent durability with 
rates of re-intervention 2-10% at 10 years, 10-20% at 15 
years and ~40% at 20 years.25 However, the incidence of 
at least moderate (stage 2) hemodynamic deterioration 
detected by echocardiography seems to be more important, 
~40% for the 10 first years after implantation.13 The 
durability of percutaneously implanted bioprosthetic 
valves is excellent at short- and medium-term and 
comparable to surgical ones, with comparative studies of 
hemodynamic deterioration providing  reassuring results.  
It should be underlined that data regarding long term 
durability are limited by the short follow-up of patients 
treated with TAVI since initially the technique was applied 
to elderly patients with many comorbidities having 
survival rates at 5 years around 50%. 
Recent studies (Table 2) interrogating the long-term 
durability of percutaneously implanted bioprosthetic 
valves report a moderate hemodynamic deterioration rate 
of 4.5-15.8% between 5 to 8 years post TAVI.26-35  
Blackman et al reported an incidence of moderate and 
severe SVD of 8.7% and 0.4% respectively at 5-10 years 
post-intervention.35 A recent analysis of NOTION study 
has found less moderate or severe SVD at 6 years after 
TAVI compared to AVR (4.8% vs 24% respectively), 
while there was no difference in BVF rates (7.5% vs 6.7%; 
p=0.89).34 
 
Table 2. Studies of TAVI bioprosthetic valves 
durability  
 
Author / 
year 
No. of 
Pts 
Median 
FU (y) 
Valve types Moderate or severe 
structural valve 
deterioration (SVD) 
Søndergaard 
et al.34 / 2019 
139 6  CoreValve 4.8% 
Durand et 
al.29 / 2019 
1043 3.9  Edwards: 70 
Sapien: 475 
Sapien XT: 512 
CoreValve:199 
Jena: 7 
11.2% (at 7 years) 
Kumar et 
al.33 / 2019 
276 3.8  Edwards: 7 
Sapien: 244 
Sapien XT: 25 
8.3% (at 5 years) 
Blackman et 
al. 35 / 2019 
241 5.8  Sapien: 45 
Sapien XT: 35 
CoreValve: 149 
Portico : 214 
9.1% 
Holy et al.32/ 
2018 
152 5 CoreValve 7.9% (actuarial) &  
4.5% (actual) at 8 yrs 
Barbanti et 
al.26 / 2018 
288 6,7 CoreValve: 238 
Sapien XT: 48 
10.38% at 8 years 
Deutsch et 
al.27 / 2018 
300 7.1 CoreValve: 214 
Sapien: 86 
14.9% at 7 years 
Gleason et 
al.31 / 2018 
391 4.2 CoreValve 10% at 5 years 
Didier et al.28 
/ 2018 
4201 - Sapien:2774 
CoreValve: 1413 
15.8% at 5 years 
 
A multicenter French study that included 1403 TAVI 
patients has used the newest European definitions for 
bioprosthetic valve deterioration and failure and found a 
BVF incidence of 1.9% at 7 years and of moderate or 
severe SVD at 7% and 4.2% respectively.10,28 
These numbers are reassuring but they should be 
confirmed by large randomized studies of TAVI with long 
follow-up among intermediate to low risk patients. On 
final analysis the choice of bioprosthetic valve should be 
based on the patient’s life expectancy and the proven 
durability of the bioprosthetic valve, which should exceed 
the patient’s life expectancy at the time of implantation. 
 
Conclusion 
Recent randomized studies support the use of TAVI 
for the treatment of symptomatic severe AS among 
intermediate and low risk patients, since it has been shown 
to be at least non inferior compared to AVR. Bioprosthetic 
valve deterioration and failure over time has been an 
important concern for surgical valves and is a major issue 
before TAVI widely expands to treat younger and low risk 
patients with prolonged life expectancy. Recent consensus 
papers proposed standardized definitions for bioprosthetic 
valve deterioration and dysfunction, which will positively 
affect the follow-up of TAVI and AVR patients with 
echocardiography (and when necessary MDCT or PET-
CT), help better understand pathophysiologic mechanisms 
and most importantly help determine the true incidence of 
SVD and BVF. Several initial studies provide reassurance 
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regarding the durability of bioprosthetic valves implanted 
with TAVI, but larger studies and several years will be still 
needed in order to have definitive answers. 
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